Business Wire

CA-DATAPLOR

18.4.2024 15:01:35 CEST | Business Wire | Press release

Share
dataplor Announces Series A Funding Led by Spark Capital to Expand Global Location Data Intelligence

dataplor, the leading provider of global location intelligence, today announced a $10.6 million Series A funding round led by Spark Capital. This round, which included participation from Quest Venture Partners, Acronym Venture Capital, Circadian Ventures, Two Lanterns Venture Partners and APA Venture Partners, will further accelerate dataplor’s ongoing expansion, building the most accurate, comprehensive and dynamically updated database of global Point of Interest (POI) data on the market.

Today, dataplor offers data coverage across more than 200 countries and territories, encompassing over 300 million locations and over 15,000 brands. Companies in industries including technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance rely on dataplor’s global, accurate coverage to power strategic decisions and investments. With this latest funding, dataplor is positioned to expand its worldwide coverage and continue building out its team.

“Our mission at dataplor has always been about unlocking the true potential of POI data, making it accessible and actionable at a global scale,” said Geoff Michener, CEO and founder of dataplor. “This funding validates our vision and market-leading product and empowers us to accelerate our efforts, driving growth while aligned to our core values of accuracy, quality and privacy.”

dataplor’s proprietary approach merges technologies including artificial intelligence, machine learning, LLMs, and a purpose built technology platform with a global team of expert human validators. This combination allows the company to gather accurate, deduplicated and verified location data while providing a framework for regular updates to the information to stay current.

“dataplor solves a critical gap for companies seeking to scale in international markets: accurate, actionable data that unlocks business opportunities,” said Alex Finkelstein, General Partner at Spark Capital. “We see a massive potential market opportunity ahead for dataplor, but we’ve also been impressed by their traction, winning dozens of Fortune 500 customers and growing revenue by an average of 2.5x year-over-year since 2020. We’re very confident in this company’s bright future.”

Finkelstein will join dataplor’s board of directors, which includes John Frankel, founding partner of ffVC.

In addition to receiving accurate, updated and global POI data coverage, dataplor’s customers also benefit from the company’s commitment to privacy. All of the information in dataplor’s datasets is gathered through direct contact with a business or through publicly available data; no personally identifiable information (PII) is used. This approach not only aligns with the company’s ethical commitments but also ensures dataplor’s customers won’t be burdened with any regulatory or legal repercussions.

About dataplor

dataplor is a leading geospatial data company that helps global enterprises grow abroad by mapping tough-to-reach markets with a privacy-first approach. As the majority of international location data is inaccurate and quickly out of date, dataplor goes several steps further than the industry standard to help the world’s largest companies in technology, mapping, search, third party logistics, consumer packaged goods (CPG), telecom, investing, real estate and finance understand intelligence about any commercial or physical location in the world, in real-time, to fuel expansion abroad.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418167357/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye